FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
4D Molecular Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$12.29+0.15 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $863.64M
- P/E (TTM)
- –
- Dividend yield
- –
4D Molecular Therapeutics, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Japan | $3.69M | $2.96M | – | – | $0 | $0 | – | – | – | – | – | – | 97.6% | – |
| United States | $90.00K | $90.00K | – | – | $15.00K | $14.00K | $1.00K | $3.00K | $5.00K | $28.00K | – | $20.16M | 2.4% | +500.0% |
| Netherlands | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $1.00K | $41.00K | – | – |
From the segment and revenue-disaggregation notes of 4D Molecular Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.